Various therapeutics such as monoclonal antibodies (CetuximabTM, NimotuzumabTM), inhibitors (GefitinibTM, ErlotinibTM) are known to trigger different EGFR signaling pathways to enhance the survival of cancer cells and to develop resistance against therapeutic agents (128). Here, EGFR is linked to cancer.